Valuation: Cann Group Limited

Market Cap 8.13M 5.64M 4.93M 4.53M 4.22M 8.01M 537M 54.36M 21.13M 264M 21.16M 20.7M 909M P/E 2024
-0.23x
P/E 2025 -0.24x
Enterprise Value 83.96M 58.23M 50.9M 46.78M 43.6M 82.7M 5.54B 562M 218M 2.73B 219M 214M 9.39B EV / Sales 2024
4.54x
EV / Sales 2025 6.2x
Free-Float
82.48%
Yield 2024 *
-
Yield 2025 -
1 week+50.00%
Current month-10.00%
1 month+12.50%
3 months-25.00%
6 months-50.00%
Current year-50.00%
1 week 0
Extreme 0.002
0
1 month 0
Extreme 0.002
0
Current year 0
Extreme 0.002
0.01
1 year 0
Extreme 0.002
0.02
3 years 0
Extreme 0.002
0.19
5 years 0
Extreme 0.002
0.44
10 years 0
Extreme 0.002
4.55
Manager TitleAgeSince
Chief Executive Officer - 2024-03-31
Director of Finance/CFO - 2024-08-13
Chief Operating Officer - -
Director TitleAgeSince
Chairman 79 2025-02-09
Director/Board Member - 2020-09-07
Director/Board Member 59 2025-03-30
Date Insider Type Main position Quantity % Market Cap.
24-06-11Buy

Chief Executive Officer

205,500 0.0469%
23-07-31Free

Chairman

142,046 0.0292%
23-07-31Buy

Director

165,515 0.0341%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+50.00%-70.00%-96.09% 5.07M
-2.01%+3.17%+53.54%+205.98% 223M
0.00%-0.68%-24.08%-27.50% 144M
0.00%+8.93%+22.00%+103.33% 127M
+4.47%-4.14%+45.28%-2.60% 92.84M
-0.79%+2.59%-36.59%-47.77% 59.79M
Average +0.28%+13.57%-1.64%+22.56% 108.65M
Weighted average by Cap. -0.12%+6.95%+19.84%+79.05%

Financials

2024 2025
Net sales 18.36M 12.73M 11.13M 10.23M 9.53M 18.08M 1.21B 123M 47.74M 596M 47.79M 46.76M 2.05B 13.25M 9.19M 8.04M 7.38M 6.88M 13.06M 875M 88.65M 34.46M 430M 34.5M 33.76M 1.48B
Net income -51.24M -35.54M -31.07M -28.55M -26.61M -50.48M -3.38B -343M -133M -1.66B -133M -131M -5.73B -22.34M -15.5M -13.55M -12.45M -11.6M -22.01M -1.48B -149M -58.1M -725M -58.17M -56.92M -2.5B
Net Debt 70.83M 49.12M 42.94M 39.46M 36.78M 69.77M 4.68B 474M 184M 2.3B 184M 180M 7.92B 75.83M 52.59M 45.97M 42.25M 39.38M 74.7M 5.01B 507M 197M 2.46B 197M 193M 8.48B
Logo Cann Group Limited
Cann Group Limited is an Australia-based company, which is focused on developing, producing, and supplying innovative cannabis medicines. The principal activities of the Company include the cultivation of medicinal cannabis for both medicinal and research purposes pursuant to the licenses and permits issued to the Company, the development and manufacture (via third party arrangements) of finished product formulations, and the pursuit and execution of various supply agreements with third parties. It operates through cultivation of the medicinal cannabis segment. The Company supplies a range of dried flower and oil products, as well as active pharmaceutical ingredients and extracts, to customers in Australia and around the world. It also owns Satipharm and its patent-protected capsule technology. The Company's research and good manufacturing practices (GMP) manufacturing facilities are near Mildura, Victoria.
Employees
-
Date Price Change Volume
26-07-03 A$0.004500 0.00% 226,752
26-07-02 A$0.004500 0.00% 228,048
26-07-01 A$0.004500 -10.00% 494,625
26-06-30 A$0.005000 +150.00% 19,506,724
26-06-29 A$0.002000 -33.33% 36,412,796